Faculty of Health Disciplines, Athabasca University, Athabasca, Alberta, Canada.
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Psychooncology. 2020 Jan;29(1):204-211. doi: 10.1002/pon.5298. Epub 2019 Dec 30.
The ACTIVATE Trial examined the efficacy of a wearable-based intervention to increase physical activity and reduce sedentary behavior in breast cancer survivors. This paper examines the effects of the intervention on health-related quality of life (HRQoL) and fatigue at 12 weeks (T2; end of intervention) and 24 weeks (T3; follow-up).
Inactive and postmenopausal women who had completed primary treatment for stage I-III breast cancer were randomized to intervention or waitlist control. Physical activity and sedentary behavior were measured by Actigraph and activPAL accelerometers at baseline (T1), end of the intervention (T2), and 12 weeks follow-up (T3). HRQoL and fatigue were measured using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue). Primary intervention effects were evaluated comparing intervention and waitlist group at T2 using repeated measures mixed effects models.
Overall, 83 women were randomized and trial retention was high (94%). A 4.6-point difference in fatigue score was observed between groups at T2 (95% CI: 1.3, 7.8) indicating improvement in fatigue profiles in the intervention group. In within groups analyses, the intervention group reported a 5.1-point increase in fatigue from baseline to T2 (95% CI: 2.0, 8.2) and a 3.3-point increase from baseline to T3 (95% CI: 0.1, 6.41).
Despite small improvements in fatigue profiles, no effects on HRQoL were observed. While the ACTIVATE Trial was associated with improvements in physical activity and sedentary behavior, more intensive or longer duration interventions may be needed to facilitate changes in HRQoL.
ACTIVATE 试验研究了一种基于可穿戴设备的干预措施对增加乳腺癌幸存者身体活动和减少久坐行为的疗效。本文研究了该干预措施对健康相关生活质量（HRQoL）和疲劳的影响，在 12 周（T2；干预结束）和 24 周（T3；随访）时进行评估。
已完成 I-III 期乳腺癌初始治疗的不活跃和绝经后女性被随机分配至干预组或候补对照组。在基线（T1）、干预结束时（T2）和 12 周随访时（T3），使用 Actigraph 和 activPAL 加速度计测量身体活动和久坐行为。使用癌症治疗功能评估-乳房（FACT-B）和慢性疾病治疗疲劳功能评估（FACIT-Fatigue）评估 HRQoL 和疲劳。使用重复测量混合效应模型，在 T2 时比较干预组和候补对照组的主要干预效果。
共有 83 名女性被随机分配，试验保留率高（94%）。T2 时两组间疲劳评分差异为 4.6 分（95%CI：1.3，7.8），表明干预组的疲劳状况有所改善。在组内分析中，干预组从基线到 T2 时疲劳增加了 5.1 分（95%CI：2.0，8.2），从基线到 T3 时疲劳增加了 3.3 分（95%CI：0.1，6.41）。
尽管疲劳状况略有改善，但 HRQoL 没有变化。尽管 ACTIVATE 试验与身体活动和久坐行为的改善相关，但可能需要更密集或更长期的干预措施来促进 HRQoL 的变化。
